文献速递淋巴瘤

弥漫大B细胞淋巴瘤:2019年诊断、风险分层与治疗更新

Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment.
PubMed 文献 · Am J Hematol · 2019-01-01

本文综述弥漫大B细胞淋巴瘤(DLBCL)的诊断、风险分层与治疗更新,强调依据细胞起源(COO)和分子特征(如双打击/三打击、c-MYC异常)进行风险适应治疗,并讨论初治与复发时的差异化策略。

要点

  • DLBCL诊断理想依靠淋巴结切除活检,显示大细胞破坏滤泡中心并表达CD20、CD79a等泛B细胞抗原。
  • COO由免疫组化染色确定,双打击或三打击病变由荧光原位杂交分析确定。
  • 非生发中心B细胞(GCB)样DLBCL对初治化疗免疫治疗反应较GCB样差;c-MYC异常者(尤其伴BCL2/BCL6易位)对初治化疗免疫治疗和复发时挽救性自体干细胞移植反应差。

核心结论

  • 本综述聚焦于根据COO和分子特征对DLBCL进行初治和复发时的差异化治疗。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • 非GCB样DLBCL(活化B细胞样和不可分类)对初治化疗免疫治疗的反应较GCB样DLBCL差。
  • 单独c-MYC异常及同时伴BCL2和/或BCL6易位(尤其当MYC易位伙伴为免疫球蛋白)者,对初治化疗免疫治疗和复发时挽救性自体干细胞移植反应差。

关键数值与推荐

  • 临床预后系统包括利妥昔单抗国际预后指数(R-IPI)、年龄调整IPI和NCCN-IPI,使用临床因素进行风险分层,但不影响治疗选择。
  • COO由免疫组化染色确定,双打击或三打击病变由荧光原位杂交分析确定。
  • 频繁复发突变的商业检测目前不常规用于指导治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma originating from the germinal center, and it represents a heterogeneous group of diseases with variable outcomes that are differentially characterized by clinical features, cell of origin (COO), molecular features, and most recently, frequently recurring mutations. DIAGNOSIS: DLBCL is ideally diagnosed from an excisional biopsy of a suspicious lymph node, which shows sheets of large cells that disrupt the underlying structural integrity of the follicle center and stain positive for pan-B-cell antigens, such as CD20 and CD79a. COO is determined by immunohistochemical stains, while molecular features such as double-hit or triple-hit disease are determined by fluorescent in situ hybridization analysis. Commercial tests for frequently recurring mutations are currently not routinely used to inform treatment. RISK STRATIFICATION: Clinical prognostic systems for DLBCL, including the rituximab International Prognostic Index, age-adjusted IPI, and NCCN-IPI, use clinical factors for the risk stratification of patients, although this does not affect the treatment approach. Furthermore, DLBCL patients with non-germinal center B-cell (GCB)-like DLBCL (activated B-cell like and unclassifiable) have a poorer response to up-front chemoimmunotherapy (CI) compared to patients with GCB-like DLBCL. Those with c-MYC-altered disease alone and in combination with translocations in BCL2 and/or BCL6 (particularly when the MYC translocation partner is immunoglobulin) respond poorly to up-front CI and salvage autologous stem cell transplant at relapse. RISK-ADAPTED THERAPY: This review will focus on differential treatment of DLBCL up-front and at the time of relapse by COO and molecular features.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019. PMID: 30859597. doi:10.1002/ajh.25460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。